A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Mar 2018
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary) ; Eribulin (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 13 Mar 2018 Planned End Date changed from 1 Aug 2020 to 1 Aug 2021.
- 14 Aug 2017 Status changed from not yet recruiting to recruiting.
- 30 Jun 2017 New trial record